For the latest COVID-19 Travel restrictions and recommendations please click here

SMi's inaugural conference on Cancer Vaccines will provide attendees with a complete view of the cancer immunotherapy field. Focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an indepth look into current advances in cancer vaccines.

This event will present itself as a perfect forum for learning about new advances in the field, presenting attendees with the latest information on technogical and regulatory updates in the field. SMi's Cancer Vaccines 2012 will explore the use of biomarkers in cancer immunotherapy developments and will provide the perfect platform for discussions into regulatory challenges faced in cancer developments as well as strategies to improve success in clinical trials.

With senior industry representatives presenting on their own exepriences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.

This exciting new event will bring together senior Pharma representatives and key academics to discuss current developments in this fast-paced field. With presentations from industry representatives from all over the pharmaceutical sector, this event promises to be a unique platform for networking and problem solving.












Learn about and consider the issues within novel vaccine discovery

Discuss methods and strategies for efficient target selection

Consider developments in vaccine delivery strategies

Understand the use of biomarkers in cancer immunotherapy

Debate the importance of overcoming immune supression in the tumor microenvironment

Evaluate manufacturing, regulatory and commercial challenges

Develop ideas and network with key industry professionals

Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Principal Scientists and Managers in the following areas:
  • Oncology
  • Formulation Development
  • Drug delivery
  • Immunology
  • Antibody engineering
  • Immunoassay development
  • Structural vaccinology
  • Immunotherapeutics
  • Translational Medicine
  • Tumor Immunology & Biology
  • Discovery Chemistry
  • Molecular Medicine
  • Immunogenetics
  • Molecular Discovery Research
  • Molecular Microbiology and Chemistry
  • Regulatory Affairs
  • Business Development
  • Genomics 

Activartis Biotech GmbH; Boehringer Ingelheim Pharma Gmbh; Cancer Research Technology Ltd; Cancer Research UK; Cancer Vaccines Ltd; Castrol Austria Ges Mbh; Cure Vac; CytoVac; DanDrit Biotech; Fanelli Haag & Kilger PLLC; Glaxosmithkline Biologicals; Helsinn Healthcare SA; Immudex; Immunocore; Imperial College London; Imperial Innovations; Innsbruck Medical University; INSERM; Institut Pasteur; Institut Universitaire D'hematologie; Interlab Central Lab Services-Worldwide Gmb H; Istituto Nazionale Tumori; JPT Peptide Technologies; Kings College London; LabCorp Clinical Trials; Merck KGaA; Merck Serono; N.N. Blokhin Cancer Research Center; NHS Trust; Novartis Vaccines and Diagnostics, Inc.; Pan Therapeutics; Pharmaceutical Company; Thomson Reuters; TriMod Therapeutics; UCL Cancer Institute; Universität Heidelberg; University of Birmingham; University of Malta; University of Nottingham; University Of Southampton; University of Tuebingen Medical School;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Nicholas Valiante

Nicholas Valiante, Head of Immunology, Novartis Vaccines and Diagnostics, Inc.

9:10 Current overview of cancer vaccines

Christian Ottensmeier

Christian Ottensmeier, Professor in Experimental Cancer Medicine, University Of Southampton

• A global overview of cancer vaccine success and failures – what can we learn from them?
• Learning from the past to improve success in novel vaccine discovery
• Potential starting points for new therapeutic vaccines
• Examples drawn from the newest vaccines in early development will illustrate the application of the growing body of knowledge in vaccine design

9:50 Development of cancer immunotherapeutics at GlaxoSmithKline Biologicals: MAGE-A3 as leade example

Patrick Therasse

Patrick Therasse, VP, Late Stage Clinical Development, Immunotherapeutics, Glaxosmithkline Biologicals

• Choice of the antigen
• Trial design for PoC
• Design of registration trial
• Characterization of predictive biomarkers

10:30 Morning Coffee

10:50 Development of mRNA vaccines

Karl-Josef Kallen

Karl-Josef Kallen, Chief Scientific Officer, Cure Vac

• Background on CureVac
• CureVac’s mRNA-based vaccination technology (infectious diseases and cancer)
• Tumor Immunotherapy
• Clinical trial data (CV9103 against PCA and CV9201 against NSCLC)

11:25 An insight on advances and challenges in cancer immunotherapy

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

• Combining most effective tumor antigens with the most effective delivery strategies to achieve positive clinical trial results
• Can plasmids ever be a successful protective vaccine strategy
• Understanding all factors involved in delivery techniques

12:00 Engineering vaccine adjuvant formulations with a focus on safety and tolerability

Nicholas Valiante

Nicholas Valiante, Head of Immunology, Novartis Vaccines and Diagnostics, Inc.

• Adapting drug discovery/development strategies to vaccine adjuvants and immuno-therapies
• Understanding the molecular basis of adjuvanticity
• Determining the minimal requirements for efficacy
• Development of stable, scalable and reproducible formulations

12:40 Networking Lunch

14:10 Identifying novel targets for cancer vaccines

Lindy Durrant

Lindy Durrant, Professor, University of Nottingham

• ImmunoBodyTM a novel DNA that uses antibodies to target antigen to antigen presenting cells
• Clinical results with ImmunoBodyTM
• Screening of high avidity CD8 responses anti-tumour responses
• Identification of novel anti-tumour CD4 epitopes

14:50 MHC Dextramers - Benefits of looking at Antigen-Specific T Cells in different stages of Cancer Immunotherapy Development

Liselotte Brix

Liselotte Brix, COO, Immudex

15:30 Afternoon Tea

15:50 Immunologically targeting the cancer phosphoproteome

Mark Cobbold

Mark Cobbold, Senior Clinical Research Fellow, University of Birmingham

• Tumour associated phosphopeptides antigens as potential novel cancer vaccines
• Assessment of immunity against phosphoantigens in health and disease
• Unique considerations for phosphopeptides as candidate vaccine candidates
• Unique advantages of targeting post-translationally modified antigens compared with conventional tumour associated antigens

16:30 Monitoring immunotherapy outcomes

Graham Pawelec

Graham Pawelec, Professor of Experimental Immunology, University of Tuebingen Medical School

• Benefits and possible problems associated with using blood
• Using TIL, do we need to?
• Developing and ‘immunoscore’
• Different factors for different patients (depending on age, type, treatment and combination)

17:10 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

9:10 Advances and challenges in the advancement of novel therapeutic cancer vaccines

Oliver Wilbert

Oliver Wilbert, Senior Director Immunotherapies , Merck KGaA

• Update on the most recent successes and promising candidates in Phase III (incl. Prostate Cancer and NSCLC (incl. STIMUVAX))
• Lessons learnt on therapeutic settings for cancer vaccines in oncology
• Key success factors for future development

9:50 Intravesical BCG and bladder cancer

Matthew Albert

Matthew Albert, Director of Immunology, Institut Pasteur

• Background on bladder cancer immunotherapy
• Lessons from one of the most successful and longstanding immunotherapy regimens
• Adapting these ideas to other areas of cancer

10:30 Morning Coffee

11:00 Monitoring tumour-specific T-cell responses in vivo

Jian Guo Chai

Jian Guo Chai, Senior Lecturer in Immunology, Imperial College London

• Introduction of HY models
• Breaking established transplantation tolerance by vaccination
• Study of tumour-specific CD8, CD4 and regulatory T cell responses in vivo
• Impact of tissue microenvironment on anti-tumour T cell response

11:40 The immunoscore as a new classification of cancer in the era of immunotherapy

Jerome Galon

Jerome Galon, Research Director, INSERM

• The importance of optimising t-cell costimulation as a therapeutic
• Engineering T cell-activating fusion proteins and immunocytokines targeted to antigens of a tumor vaccine
• Evaluating T cell stimulatory activity
• How can we control this activity?

12:20 Networking Lunch

13:50 Utilizing Allogeneic Cells in Cancer Immunotherapy

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

  • Overview of the use of cell-based immunotherapeutics in Cancer Vaccines
  • Developing combination therapies
  • Targeting the right antigen with the right delivery method
  • 14:30 Final steps in developing next generation dendritic cell-based cancer immune therapy

    Thomas Felzmann

    Thomas Felzmann, CEO, Activartis Biotech GmbH

  • First results from a randomised clinical trial for the treatment of Glioblastoma Multiforme using whole tumour cell lysate-charged danger signal-emulated dendritic cells
  • Basic concepts and rational for the design of the most advanced “next generation“ (post-Provenge) DC cancer immune therapy
  • Cancer immune therapy is a novel independent treatment paradigm that will develop into the fourth pillar of cancer treatment
  • Advances in manufacturing, quality control, and logistics of distribution enable an area-wide supply of all eligible patients
  • Lessons learned
  • 15:10 Afternoon Tea

    15:40 Overcoming challenges in cancer vaccine clinical development

    Eric Leire

    Eric Leire, CEO, DanDrit Biotech

    • What should be the role of a Phase II?
    • Competing for patients and clinical investigators
    • Are the increasing costs of clinical trials unavoidable?

    16:20 Alphaviruses as vectors in cancer therapy

    Kenneth Lundstrom

    Kenneth Lundstrom, CEO, Pan Therapeutics

    • Delivery of viral particles, RNA and DNA
    • Cancer vaccines
    • Tumor targeting through liposome encapsulation
    • Protection against host immune response
    • Immunotherapy
    • Clinical trials

    17:00 Chairman’s Closing Remarks and Close of Day Two



    Oliver Wilbert

    Oliver Wilbert

    Senior Director Immunotherapies , Merck KGaA

    Christian Ottensmeier

    Professor in Experimental Cancer Medicine, University Of Southampton
    Christian Ottensmeier

    Eric Leire

    CEO, DanDrit Biotech
    Eric Leire

    Graham Pawelec

    Professor of Experimental Immunology, University of Tuebingen Medical School
    Graham Pawelec

    Jerome Galon

    Research Director, INSERM
    Jerome Galon

    Jian Guo Chai

    Senior Lecturer in Immunology, Imperial College London
    Jian Guo Chai

    John Maudsley

    CEO, Cancer Vaccines Ltd
    John Maudsley

    Karl-Josef Kallen

    Chief Scientific Officer, Cure Vac
    Karl-Josef Kallen

    Kenneth Lundstrom

    CEO, Pan Therapeutics
    Kenneth Lundstrom

    Lindy Durrant

    Professor, University of Nottingham
    Lindy Durrant

    Liselotte Brix

    COO, Immudex
    Liselotte Brix

    Mark Cobbold

    Senior Clinical Research Fellow, University of Birmingham
    Mark Cobbold

    Matthew Albert

    Director of Immunology, Institut Pasteur
    Matthew Albert

    Nicholas Valiante

    Head of Immunology, Novartis Vaccines and Diagnostics, Inc.
    Nicholas Valiante

    Oliver Wilbert

    Senior Director Immunotherapies , Merck KGaA
    Oliver Wilbert

    Patrick Therasse

    VP, Late Stage Clinical Development, Immunotherapeutics, Glaxosmithkline Biologicals
    Patrick Therasse

    Sonia Quaratino

    Senior Medical Director and Immunology Advisor, Merck Serono
    Sonia Quaratino

    Thomas Felzmann

    CEO, Activartis Biotech GmbH
    Thomas Felzmann

    Copthorne Tara Hotel

    Scarsdale Place
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out